Perceptive Advisors’s Disc Medicine IRON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-450,743
Closed -$35.8M 114
2025
Q4
$35.8M Buy
+450,743
New +$38.1M 0.64% 43
2025
Q2
Sell
-150,000
Closed -$7.45M 97
2025
Q1
$7.45M Buy
+150,000
New +$8.34M 0.26% 61
2024
Q4
Sell
-387,017
Closed -$19M 110
2024
Q3
$19M Sell
387,017
-166,420
-30% -$7.81M 0.4% 59
2024
Q2
$24.9M Sell
553,437
-386,429
-41% -$13.1M 0.6% 48
2024
Q1
$58.5M Sell
939,866
-83,179
-8% -$5.39M 1.02% 33
2023
Q4
$59.1M Buy
1,023,045
+127,404
+14% +$6.52M 1.32% 22
2023
Q3
$42.1M Buy
895,641
+152,803
+21% +$7.64M 1.4% 22
2023
Q2
$33M Buy
+742,838
New +$26.4M 0.95% 33

Other funds holding IRON

Perceptive Advisors's IRON Position: Q1 2026 in Review

Perceptive Advisors sold out of Disc Medicine (IRON) in Q1 2026, closing a stake of 450,743 shares — an estimated $35.8M sold.

Perceptive Advisors first reported a position in IRON in Q2 2023 and held it in 8 quarters. The position peaked at $59.1M in Q4 2023. 203 funds tracked by Wall St. Rank hold IRON as of Q1 2026.

  • Perceptive Advisors reported no remaining Disc Medicine position as of Q1 2026 after selling out during the quarter.
  • Perceptive Advisors sold 450,743 Disc Medicine shares in Q1 2026, an estimated $35.8M.
  • Perceptive Advisors first reported a position in Disc Medicine in Q2 2023 and held it in 8 quarters.
  • Perceptive Advisors's Disc Medicine position peaked at $59.1M in Q4 2023.
  • 203 funds tracked by Wall St. Rank held Disc Medicine as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.